Minerva Neurosciences (NERV) Competitors $1.35 +0.01 (+0.75%) Closing price 04/10/2025 03:47 PM EasternExtended Trading$1.44 +0.10 (+7.04%) As of 04/10/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NERV vs. ITRM, ATNM, MRSN, XFOR, DYAI, OTLK, CTMX, MIST, PEPG, and PRLDShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Iterum Therapeutics (ITRM), Actinium Pharmaceuticals (ATNM), Mersana Therapeutics (MRSN), X4 Pharmaceuticals (XFOR), Dyadic International (DYAI), Outlook Therapeutics (OTLK), CytomX Therapeutics (CTMX), Milestone Pharmaceuticals (MIST), PepGen (PEPG), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. Iterum Therapeutics Actinium Pharmaceuticals Mersana Therapeutics X4 Pharmaceuticals Dyadic International Outlook Therapeutics CytomX Therapeutics Milestone Pharmaceuticals PepGen Prelude Therapeutics Iterum Therapeutics (NASDAQ:ITRM) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking. Does the media refer more to ITRM or NERV? In the previous week, Minerva Neurosciences had 3 more articles in the media than Iterum Therapeutics. MarketBeat recorded 4 mentions for Minerva Neurosciences and 1 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 1.87 beat Minerva Neurosciences' score of 0.63 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Iterum Therapeutics Very Positive Minerva Neurosciences Positive Which has preferable valuation & earnings, ITRM or NERV? Iterum Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$1.31-0.84Minerva NeurosciencesN/AN/A-$30M$0.197.11 Is ITRM or NERV more profitable? Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -90.85% Minerva Neurosciences N/A N/A -6.74% Do analysts rate ITRM or NERV? Iterum Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 354.55%. Minerva Neurosciences has a consensus price target of $5.00, suggesting a potential upside of 270.37%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Iterum Therapeutics is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, ITRM or NERV? Iterum Therapeutics has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Does the MarketBeat Community favor ITRM or NERV? Minerva Neurosciences received 206 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. However, 62.95% of users gave Iterum Therapeutics an outperform vote while only 55.97% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformIterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% Minerva NeurosciencesOutperform Votes34755.97% Underperform Votes27344.03% Do insiders and institutionals hold more shares of ITRM or NERV? 9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 9.2% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryIterum Therapeutics beats Minerva Neurosciences on 9 of the 14 factors compared between the two stocks. Remove Ads Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.44M$6.09B$5.17B$7.38BDividend YieldN/A3.02%5.35%4.26%P/E Ratio-3.076.5021.7617.55Price / SalesN/A203.67351.8589.69Price / CashN/A65.6738.1534.64Price / Book-0.335.456.163.81Net Income-$30M$141.10M$3.19B$247.05M7 Day Performance-1.46%1.61%-0.09%0.58%1 Month Performance-12.90%-13.68%-2.89%-8.66%1 Year Performance-46.85%-20.74%2.66%-6.60% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences3.478 of 5 stars$1.35+0.7%$5.00+270.4%-45.3%$9.44MN/A-3.079Analyst ForecastNews CoverageITRMIterum Therapeutics1.8734 of 5 stars$1.11-1.8%$5.00+350.5%-32.9%$38.39MN/A-0.8510Gap DownATNMActinium Pharmaceuticals1.7044 of 5 stars$1.22-5.4%$7.40+506.6%N/A$38.06M$81,000.00-0.8830Analyst DowngradeGap DownMRSNMersana Therapeutics4.4149 of 5 stars$0.31+0.8%$4.00+1,210.2%-92.9%$38.05M$40.50M-0.50150Positive NewsGap DownXFORX4 Pharmaceuticals4.4278 of 5 stars$0.21-1.2%$2.83+1,235.8%-82.7%$36.83M$2.56M-2.3680Positive NewsGap DownDYAIDyadic International2.2826 of 5 stars$1.22-2.4%$6.00+391.8%-33.7%$36.71M$3.50M-5.307Positive NewsGap DownOTLKOutlook Therapeutics1.2562 of 5 stars$1.14-5.0%$10.20+794.7%-86.2%$36.50MN/A-0.1520CTMXCytomX Therapeutics3.9702 of 5 stars$0.43-5.3%$5.02+1,064.0%-76.4%$36.49M$138.10M2.54170MISTMilestone Pharmaceuticals1.9095 of 5 stars$0.68-2.0%$17.00+2,392.3%-55.1%$36.39M$1M-0.8430PEPGPepGen2.2677 of 5 stars$1.10+0.5%$10.33+839.4%-90.2%$35.96MN/A-0.3730PRLDPrelude Therapeutics2.3772 of 5 stars$0.65-4.0%$4.00+517.2%-87.0%$35.75M$7M-0.36120Analyst ForecastAnalyst RevisionGap Down Remove Ads Related Companies and Tools Related Companies Iterum Therapeutics Alternatives Actinium Pharmaceuticals Alternatives Mersana Therapeutics Alternatives X4 Pharmaceuticals Alternatives Dyadic International Alternatives Outlook Therapeutics Alternatives CytomX Therapeutics Alternatives Milestone Pharmaceuticals Alternatives PepGen Alternatives Prelude Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NERV) was last updated on 4/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
